Article
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.
The pharmacogenomics journal - 1 Feb 2012
Leventhal A M, David S P, Brightman M, Strong D, McGeary J E, Brown R A, Lloyd-Richardson E E, Munafò M, Uhl G R, Niaura R
Abstract excerpt
Smokers (≥10 cigarettes per day, N=331) of European ancestry taking part in a double-blind placebo-controlled randomized trial of 12 weeks of treatment with bupropion along with counseling for smoking cessation were genotyped for a variable number of tandem repeats polymorphism in exon III of the dopamine D4 receptor gene. Generalized estimating equations predicting point-prevalence abstinence at end of treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.